terça-feira, abril 24, 2007
Maraviroc avança na FDA
The FDA Antiviral Drug Advisory Committee voted unanimously to recommend accelerated approval of Maraviroc, the first CCR5 inhibitor HIV drug, by the FDA. We probably will hear from the FDA within a few months. The FDA usually follow advise by this panel so we can expect FDA approval.
Ongoing now is discussion of post-approval studies.